SciELO - Scientific Electronic Library Online

vol.82 issue2Anterograde flow compromise of a patent left internal mammary artery graft from a proximal subclavian artery stenosis. Myocardial ischemia not driven by the coronary-subclavian steal syndrome mechanismCardiac rehabilitation in congenital heart disease author indexsubject indexsearch form
Home Pagealphabetic serial listing  

Services on Demand




Related links

  • Have no similar articlesSimilars in SciELO


Archivos de cardiología de México

On-line version ISSN 1665-1731Print version ISSN 1405-9940


FILGUEIRAS-RAMA, David et al. Basic mechanisms of the new antiarrhythmic drugs in atrial fibrillation. Arch. Cardiol. Méx. [online]. 2012, vol.82, n.2, pp.139-152. ISSN 1665-1731.

Atrial fibrillation (AF) is the most common sustained arrhythmia seen in clinical practice. Despite of new technological breakthroughs and the understanding of the mechanisms underlying AF, based on animal models and ablation procedures in patients, the antiarrhythmic drugs remain the main therapeutic strategy to restore and maintain the sinus rhythm. New antiarrhythmic drugs are already available in the clinical practice and many others are under development. The new antiarrhythmic drugs have the capability to block atrial-specific ionic currents, which are involved in the maintenance of the arrhythmia. Parallel, increasing evidence supports the use of compounds to regulate the arrhythmogenic atrial substrate involved in the long-term maintenance of the arrhythmia (upstream therapies). This article reviews the new antiarrhythmic drugs and upstream therapies, based on the current knowledge of the mechanisms involved in the maintenance of AF.

Keywords : Atrial fibrillation; Antiarrhythmic drugs; Ion currents; Atrial remodeling; Dronedarone; Spain.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License